Based on the aggregated intelligence of 170,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, orthopedic devices giant Stryker (NYSE: SYK) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at Stryker's business and see what CAPS investors are saying about the stock right now.

Stryker facts

Headquarters (Founded) Kalamazoo, Mich. (1941)
Market Cap $20.6 billion
Industry Health-care equipment
Trailing-12-Month Revenue $7.16 billion
Management CEO Stephen MacMillan (since 2005)
CFO Curt Hartman (since 2009)
Return on Equity (Average, Past 3 Years) 19.1%
Cash / Debt $4.5 billion / $996.4 million
Dividend Yield 1.2%
Competitors Zimmer Holdings (NYSE: ZMH)
Johnson & Johnson (NYSE: JNJ)

Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.

On CAPS, 98% of the 1,410 members who have rated Stryker believe the stock will outperform the S&P 500 going forward. These bulls include tekennedy and All-Star kidderpeabodyny, who is ranked in the top 1% of our community.

This past summer , tekennedy touched on the tailwinds working in Stryker's favor: "A high ROE business with the ability to grow. Demographics should lead revenue to grow faster than market. Current pricing is attractive for long-term investors."

Stryker's leadership position in orthopedic implants and solid balance sheet make it one of our community's favorite plays on the aging baby boomer demographic. Over the next five years, Stryker is even expected to grow profits at a faster rate (10.5% per annum) than close foes Zimmer (9.7%) and Johnson & Johnson (6.1%), as well as other medical device giants like Medtronic (NYSE: MDT) (10%) and Boston Scientific (NYSE: BSX) (8.3%).  

CAPS All-Star kidderpeabodyny expands on why Stryker is all set to outperform:

[T]he majority of S&P 500 companies cannot keep up with Stryker's excellent EPS growth rate. ... Also, [Stryker] is a great entry point again, as it's well off both its high for the year, and at the low end of it's historical PE range which isn't far above its EPS growth rate. It also must be sitting on a pile of cash which will lead to either higher dividends, favorable acquisitions or an outright takeover by someone else!

What do you think about Stryker, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!  

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Stryker is a Motley Fool Inside Value choice. Johnson & Johnson is an Income Investor choice, and Motley Fool Options has recommended a diagonal call position on it. The Fool owns shares of Johnson & Johnson and Medtronic. Try any of our Foolish newsletter services free for 30 days.

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.